Myocardial viability heart failure perspectiveBock, Ashley; Estep, Jerry D.Current Opinion in Cardiology: September 2019 - Volume 34 - Issue 5 - p 459–465 doi: 10.1097/HCO.0000000000000651 IMAGING AND HEART FAILURE: MYOCARDIAL STRAIN Edited by Sherif Nagueh Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review This review highlights the different imaging modalities available to assess myocardial viability in patients with heart failure and coronary artery disease (CAD) being considered for revascularization. Recent findings Myocardial viability can be determined by a variety of cardiac imaging modalities. Recent studies have confirmed the use of cardiovascular magnetic resonance imaging (CMR) in patients with heart failure and CAD, suggesting that those who undergo revascularization but have evidence of residual viable or ‘jeopardized’ myocardium have increased mortality compared with those who achieve complete revascularization. The PET and Recovery Following Revascularization (PARR)-2 trial assessed whether viability noted on PET imaging in patients with severe LV dysfunction correlated with recovery of LV function and response to revascularization. The 5-year extension of the PARR-2 study noted a significant decrease in the composite outcome of cardiac death, myocardial infarction, or cardiac hospitalization in patient assessments adherent to PET-guided viability recommendations. Summary On the basis of the current available data, viability testing is reasonable in individuals with ICM, as identified by coronary angiography in whom complete revascularization can be achieved. Whenever available, the use of CMR or PET is preferred because of better resolution and increased sensitivity to detect myocardial viability. Cleveland Clinic Foundation, Cleveland, Ohio, USA Correspondence to Jerry D. Estep, MD, Cleveland Clinic Foundation, 9500 Euclid Avenue J3-4, Cleveland, OH 44195, USA. Tel: +1 216 444 7646; fax: +1 216 636 6974; iPhone: +1 216 314 1711; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.